TABLE 1.

PMR value of candidate genes in tissue and serum samples of patients with epithelial ovarian carcinoma and healthy control group. PMR: percentage of methylated reference. p-value: Mann-Whitney U two-tailed tests. ^aThe PMR value of HOXA9 and HIC1 gene in tissue and serum samples of patients with epithelial ovarian carcinoma and healthy control group has been previously described (Singh et al., 2020).

Gene	Parameter	No. of patients	Mean ± Std.Error	Min	Max	25th	50th	75th	p-value
HOXA9a	Tissue PMR
	Tumor	85	32.83 ± 3.02	0.29	97.54	8.78	24.72	49.34	<0.0001***
	Healthy	35	2.72 ± 0.31	0.14	6.68	1.32	2.53	3.8
	Serum PMR
	Tumor	45	13.2 ± 2.52	0.05	87.42	1.97	7.45	18.95	<0.0001***
	Healthy	25	1.45 ± 0.21	0.18	3.57	0.46	1.35	2.30
HIC1a	Tissue PMR
	Tumor	85	28.54 ± 2.72	0.14	88.82	8.07	22.05	45.98	<0.0001***
	Healthy	35	3.47 ± 0.39	0.13	10.65	1.97	3.33	3.93
	Serum PMR
	Tumor	45	12.98 ± 2.21	0.06	58.68	3.28	7.96	14.91	<0.0001***
	Healthy	25	1.67 ± 0.26	0.06	3.79	0.35	1.58	2.78
SOX1	Tissue PMR
	Tumor	85	33.24 ± 3.35	0.45	96.53	5.17	19.64	60.53	<0.0001***
	Healthy	35	2.76 ± 0.29	0.74	6.52	1.46	2.14	3.81
	Serum PMR
	Tumor	45	16.09 ± 3.25	0.19	80.61	2.14	4.60	28.04	<0.0001***
	Healthy	25	1.84 ± 0.24	0.22	4.15	0.61	1.73	2.72
RASSF1A	Tissue PMR
	Tumor	85	30.97 ± 3.46	0.49	98.42	3.60	15.10	58.28	<0.0001***
	Healthy	35	3.24 ± 0.31	0.59	8.09	2.10	2.97	4.20
DAPK1	Tissue PMR
	Tumor	85	30.82 ± 3.24	0.51	94.87	3.13	27.19	55.9	<0.0001***
	Healthy	35	3.11 ± 0.41	0.33	11.18	1.48	2.24	4.67
SFRP1	Tissue PMR
	Tumor	85	24.71 ± 2.94	0.34	96.53	3.93	10.09	40.62	<0.0001***
	Healthy	35	3.30 ± 0.32	0.87	8.72	1.78	3.17	4.19
SPARC	Tissue PMR
	Tumor	85	25.55 ± 3.36	0.03	99.38	2.36	10.43	44.66	<0.0001***
	Healthy	35	3.39 ± 0.42	0.05	8.77	1.40	3.12	5.59